PT  - JOURNAL ARTICLE
AU  - IVETA KOLAROVA
AU  - LADISLAV DUSEK
AU  - ALES RYSKA
AU  - KAREK ODRAZKA
AU  - MARTIN DOLEZEL
AU  - JAROSLAV VANASEK
AU  - BOHUSLAV MELICHAR
AU  - JIRI PETERA
AU  - TOMAS BUCHLER
AU  - MILAN VOSMIK
AU  - KATARINA PETRAKOVA
AU  - PETRA TERAROVA
AU  - ZDENA VILASOVA
AU  - JIRI JARKOVSKY
TI  - Impact of Hormone Receptor Status on the Behaviour of HER2+ Breast Cancer
AID  - 10.21873/invivo.12183
DP  - 2020 Nov 01
TA  - In Vivo
PG  - 3441--3449
VI  - 34
IP  - 6
4099  - http://iv.iiarjournals.org/content/34/6/3441.short
4100  - http://iv.iiarjournals.org/content/34/6/3441.full
SO  - In Vivo2020 Nov 01; 34
AB  - Background/Aim: The study aimed to evaluate differences in the overall survival of HER2+ breast cancer patients treated with regard to their hormone receptors negativity or positivity. We evaluated a cohort of patients treated with trastuzumab in the Czech Republic. Patients and Methods: The present study is a retrospective analysis of patients whose data were recorded in a nationwide non-interventional, post-authorisation database BREAST. After propensity score matching of data, the cohort included 4,532 patients. Results: A significant difference in overall survival (OS) of the entire cohort was found between patients with and without hormone dependence. The OS was significantly higher in the group of patients with hormone receptor-positive (HR+) tumours in the following cohorts: patients treated with neoadjuvant therapy, patients with advanced disease, G2 tumours, stage III and IV and in patients with stage II and III of G2 tumours. Conclusion: Increased OS rates were found in several subgroups of patients with HR+/HER2+ tumours compared to those with HR-/HER2+ tumours. Better outcomes of HR+/HER2+ patients were only observed in the first four/five years of follow-up, and the differences disappeared over time.